FENNEC PHARMACEUTICALS INC (FRX.CA) Fundamental Analysis & Valuation

TSX:FRX • CA31447P1009

Current stock price

8.87 CAD
+0.42 (+4.97%)
Last:

This FRX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. FRX.CA Profitability Analysis

1.1 Basic Checks

  • In the past year FRX has reported negative net income.
  • In the past year FRX has reported a negative cash flow from operations.
  • In the past 5 years FRX always reported negative net income.
  • In the past 5 years FRX reported 4 times negative operating cash flow.
FRX.CA Yearly Net Income VS EBIT VS OCF VS FCFFRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M

1.2 Ratios

  • With a decent Return On Assets value of -13.81%, FRX is doing good in the industry, outperforming 72.73% of the companies in the same industry.
  • FRX's Return On Equity of -27.46% is fine compared to the rest of the industry. FRX outperforms 68.18% of its industry peers.
Industry RankSector Rank
ROA -13.81%
ROE -27.46%
ROIC N/A
ROA(3y)-24.83%
ROA(5y)-47.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FRX.CA Yearly ROA, ROE, ROICFRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400 600 800

1.3 Margins

  • Looking at the Gross Margin, with a value of 91.57%, FRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of FRX has remained more or less at the same level.
  • FRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5YN/A
FRX.CA Yearly Profit, Operating, Gross MarginsFRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. FRX.CA Health Analysis

2.1 Basic Checks

  • FRX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, FRX has more shares outstanding
  • FRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FRX.CA Yearly Shares OutstandingFRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
FRX.CA Yearly Total Debt VS Total AssetsFRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • FRX has an Altman-Z score of 0.39. This is a bad value and indicates that FRX is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 0.39, FRX perfoms like the industry average, outperforming 59.09% of the companies in the same industry.
  • FRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.39
ROIC/WACCN/A
WACCN/A
FRX.CA Yearly LT Debt VS Equity VS FCFFRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 6.37 indicates that FRX has no problem at all paying its short term obligations.
  • FRX has a Current ratio of 6.37. This is amongst the best in the industry. FRX outperforms 81.82% of its industry peers.
  • A Quick Ratio of 6.23 indicates that FRX has no problem at all paying its short term obligations.
  • FRX has a better Quick ratio (6.23) than 86.36% of its industry peers.
Industry RankSector Rank
Current Ratio 6.37
Quick Ratio 6.23
FRX.CA Yearly Current Assets VS Current LiabilitesFRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. FRX.CA Growth Analysis

3.1 Past

  • FRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -486388759756013504.00%.
  • The Revenue has decreased by -6.09% in the past year.
  • The Revenue has been growing by 204.69% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-486388759756013500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)-6.09%
Revenue growth 3Y207.19%
Revenue growth 5Y204.69%
Sales Q2Q%73.84%

3.2 Future

  • FRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 63.60% yearly.
  • Based on estimates for the next years, FRX will show a very strong growth in Revenue. The Revenue will grow by 35.41% on average per year.
EPS Next Y259.3%
EPS Next 2Y145.81%
EPS Next 3Y97.1%
EPS Next 5Y63.6%
Revenue Next Year60.4%
Revenue Next 2Y50.43%
Revenue Next 3Y44.38%
Revenue Next 5Y35.41%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
FRX.CA Yearly Revenue VS EstimatesFRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M
FRX.CA Yearly EPS VS EstimatesFRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

4

4. FRX.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • FRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 15.09, the valuation of FRX can be described as correct.
  • Based on the Price/Forward Earnings ratio, FRX is valued cheaply inside the industry as 86.36% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of FRX to the average of the S&P500 Index (21.36), we can say FRX is valued slightly cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 15.09
FRX.CA Price Earnings VS Forward Price EarningsFRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FRX.CA Per share dataFRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • FRX's earnings are expected to grow with 97.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y145.81%
EPS Next 3Y97.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FRX.CA Dividend Analysis

5.1 Amount

  • No dividends for FRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FRX.CA Fundamentals: All Metrics, Ratios and Statistics

FENNEC PHARMACEUTICALS INC

TSX:FRX (5/1/2026, 7:00:00 PM)

8.87

+0.42 (+4.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-24
Earnings (Next)05-07
Inst Owners49.46%
Inst Owner ChangeN/A
Ins Owners3.34%
Ins Owner ChangeN/A
Market Cap305.84M
Revenue(TTM)44.64M
Net Income(TTM)-9.74M
Analysts84.62
Price Target20.72 (133.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-185.87%
Min EPS beat(2)-380.11%
Max EPS beat(2)8.37%
EPS beat(4)2
Avg EPS beat(4)-128.87%
Min EPS beat(4)-380.11%
Max EPS beat(4)55.84%
EPS beat(8)3
Avg EPS beat(8)-155.39%
EPS beat(12)4
Avg EPS beat(12)-136.63%
EPS beat(16)6
Avg EPS beat(16)-108.59%
Revenue beat(2)1
Avg Revenue beat(2)2.53%
Min Revenue beat(2)-3.48%
Max Revenue beat(2)8.54%
Revenue beat(4)2
Avg Revenue beat(4)2.34%
Min Revenue beat(4)-3.48%
Max Revenue beat(4)8.54%
Revenue beat(8)3
Avg Revenue beat(8)-8.98%
Revenue beat(12)5
Avg Revenue beat(12)-5.98%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.8%
PT rev (3m)1%
EPS NQ rev (1m)-119.99%
EPS NQ rev (3m)-108.33%
EPS NY rev (1m)-36.25%
EPS NY rev (3m)-30.49%
Revenue NQ rev (1m)-2.45%
Revenue NQ rev (3m)-13.77%
Revenue NY rev (1m)-6.08%
Revenue NY rev (3m)-6.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 15.09
P/S 5.01
P/FCF N/A
P/OCF N/A
P/B 6.31
P/tB 6.31
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)0.59
Fwd EY6.63%
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS1.77
BVpS1.41
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -13.81%
ROE -27.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.57%
FCFM N/A
ROA(3y)-24.83%
ROA(5y)-47.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.92%
GM growth 5YN/A
F-Score1
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.37
Quick Ratio 6.23
Altman-Z 0.39
F-Score1
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-486388759756013500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y259.3%
EPS Next 2Y145.81%
EPS Next 3Y97.1%
EPS Next 5Y63.6%
Revenue 1Y (TTM)-6.09%
Revenue growth 3Y207.19%
Revenue growth 5Y204.69%
Sales Q2Q%73.84%
Revenue Next Year60.4%
Revenue Next 2Y50.43%
Revenue Next 3Y44.38%
Revenue Next 5Y35.41%
EBIT growth 1Y-322.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1731.03%
EBIT Next 3Y212.19%
EBIT Next 5YN/A
FCF growth 1Y-146.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-146.23%
OCF growth 3YN/A
OCF growth 5YN/A

FENNEC PHARMACEUTICALS INC / FRX.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of FENNEC PHARMACEUTICALS INC (FRX.CA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to FRX.CA.


What is the valuation status of FENNEC PHARMACEUTICALS INC (FRX.CA) stock?

ChartMill assigns a valuation rating of 4 / 10 to FENNEC PHARMACEUTICALS INC (FRX.CA). This can be considered as Fairly Valued.


How profitable is FENNEC PHARMACEUTICALS INC (FRX.CA) stock?

FENNEC PHARMACEUTICALS INC (FRX.CA) has a profitability rating of 2 / 10.


Can you provide the financial health for FRX stock?

The financial health rating of FENNEC PHARMACEUTICALS INC (FRX.CA) is 7 / 10.


What is the earnings growth outlook for FENNEC PHARMACEUTICALS INC?

The Earnings per Share (EPS) of FENNEC PHARMACEUTICALS INC (FRX.CA) is expected to grow by 259.3% in the next year.